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ORIGINAL INVESTIGATION 
Joint analysis of left ventricular 
expression and circulating plasma levels 
of Omentin after myocardial ischemia
Louis A. Saddic1, Sarah M. Nicoloro2, Olga T. Gupta3, Michael P. Czech4, Joshua Gorham5, Stanton K. Shernan6, 
Christine E. Seidman7, Jon G. Seidman5, Sary F. Aranki8, Simon C. Body6, Timothy P. Fitzgibbons9† 
and Jochen D. Muehlschlegel6*† 
Abstract 
Background: Omentin-1, also known as Intelectin-1 (ITLN1), is an adipokine with plasma levels associated with dia-
betes, obesity, and coronary artery disease. Recent studies suggest that ITLN1 can mitigate myocardial ischemic injury 
but the expression of ITLN1 in the heart itself has not been well characterized. The purpose of this study is to discern 
the relationship between the expression pattern of ITLN1 RNA in the human heart and the level of circulating ITLN1 
protein in plasma from the same patients following myocardial ischemia.
Methods: A large cohort of patients (n = 140) undergoing elective cardiac surgery for aortic valve replacement were 
enrolled in this study. Plasma and left ventricular biopsy samples were taken at the beginning of cardiopulmonary 
bypass and after an average of 82 min of ischemic cross clamp time. The localization of ITLN1 in epicardial adipose 
tissue (EAT) was also further characterized with immunoassays and cell fate transition studies.
Results: mRNA expression of ITLN1 decreases in left ventricular tissue after acute ischemia in human patients (mean 
difference 280.48, p = 0.001) whereas plasma protein levels of ITLN1 increase (mean difference 5.24, p < 0.001). 
Immunohistochemistry localized ITLN1 to the mesothelium or visceral pericardium of EAT. Epithelial to mesenchymal 
transition in mesothelial cells leads to a downregulation of ITLN1 expression.
Conclusions: Myocardial injury leads to a decrease in ITLN1 expression in the heart and a corresponding increase in 
plasma levels. These changes may in part be due to an epithelial to mesenchymal transition of the cells that express 
ITLN1 following ischemia.
Trial Registration Clinicaltrials.gov ID: NCT00985049
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Introduction
Adipose tissue is a complex organ whose functions 
extend well beyond its canonical role in energy stor-
age [1–3]. Adipose tissue can act as an endocrine organ 
through the secretion of adipokines which have the abil-
ity to act locally and remotely. Adipokines have diverse 
roles including the regulation of angiogenesis, metabo-
lism, inflammation, and cell survival/death in many tissue 
types. Recently, investigators have begun to uncover the 
pivotal role these secreted substances have in many path-
ological processes including cardiovascular disease [4–6].
Omentin-1, also know as Intelectin-1 (ITLN1), is an 
adipokine that in humans is primarily expressed in vis-
ceral adipose tissue (VAT), with very little expression in 
subcutaneous adipose tissue (SAT) [7]. More specifically, 
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the vast majority of ITLN1 expression from adipose tis-
sue is derived from the stromal vascular compartment 
with only trace amounts produced in adipocytes [8]. This 
is in contrast to many other adipokines which are pri-
marily expressed in fat cells [7]. In humans, ITLN1 can 
be detected in the circulation, and the level of this cir-
culating pool of protein has been correlated with many 
disease processes. For example, the plasma concentration 
of ITLN1 is reduced in patients with obesity and diabetes 
[9, 10]. With respect to cardiovascular disease, ITLN1 is 
decreased in metabolic syndrome patients with carotid 
atherosclerosis [11] along with patients with coronary 
artery disease (CAD) [12, 13]. Functionally, ITLN1 has 
been shown to reduce TNF-induced vascular inflam-
mation in human endothelial cells [14]. In rats, ITLN1 
promotes vasodilation in blood vessels [15] and protects 
against cerebral ischemia by promoting angiogenesis 
and inhibiting apoptosis through stimulating AKT and 
endothelial nitric oxide synthase [16]. A recent study also 
showed that systemic administration of human ITLN1 
in mice leads to a reduction in infarct size and myocyte 
apoptosis after ischemia/reperfusion injury through 
phosphorylation of AMPK and AKT [17]. These protec-
tive properties of ITLN1 are further substantiated by 
other studies which have shown that increasing levels of 
plasma ITLN1 in humans correlate with higher myocar-
dial index scores [17] and a lower frequency of ischemic 
EKG changes [18].
Despite these preliminary studies, the expression of 
this cardioprotective adipokine in the heart has not been 
well characterized. Studies have shown that the epicardial 
fat, a special type of visceral fat, expresses high amounts 
of ITLN1 and this expression may be related to underly-
ing CAD [19, 20]. Early studies on the global expression 
of ITLN1 demonstrated that this adipokine has low levels 
of expression in other organs including the heart [7] but 
further studies in humans have been limited given the 
difficulty of obtaining human heart tissue. Therefore, we 
sought to determine the effects of myocardial ischemia 
on the expression of ITLN1 in the human left ventricle 
and circulating levels of ITLN1 protein in a large popula-
tion of patients.
Methods
Human subjects and left ventricular samples
Patients presenting for elective aortic valve replacement 
surgery by a single surgeon were enrolled in this study. 
They provided written informed consent with Institu-
tional Review Board approval. Clinical characteristics of 
the study population are shown in Table 1. Patients were 
deemed to have CAD if obstructive lesions were noted 
on left heart catheterization just prior to aortic valve sur-
gery requiring concomitant revascularization of at least 
one vessel. Punch biopsies (~3–5 μg total RNA content) 
were obtained intra-operatively from the site of a rou-
tinely placed surgical vent in the anterolateral apical left 
ventricle at the initiation of cardiopulmonary bypass 
(CPB) and again after an average of 81.73 ±  27.89  min 
of aortic cross clamp time. Specifically, the biopsies were 
taken from within the myocardium and did not include 
infarcted tissue. Pre-ischemia and post-ischemia biop-
sies were taken from the same site in the track made for 
the LV vent. During aortic cross clamping, the heart was 
infused with intermittent cold blood cardioplegia (8:1 
blood to crystalloid ratio) for myocardial protection.
RNA sequencing
Tissue samples were immediately placed in  RNAlater® 
(Ambion, Life Technologies, USA), and after 48  h at 
+4  °C were stored at −80  °C until RNA extraction. 
Total RNA was isolated with Trizol and RNA qual-
ity was assessed using the Agilent Bioanalyzer 2100 
(Agilent) with no samples being excluded for poor 
quality. Library preparation and sequencing has been 
Table 1 Clinical characteristics of study patients
Statistics are mean values and standard deviations for continuous variables 
except ITLN1 mRNA levels which are described with median and interquartile 
range. Statistics for categorical variables are number of patients and percentage 
of patients
LV EF left ventricular ejection fraction, AX time aortic cross clamp time, BMI body 
mass index, CAD coronary artery disease, HgA1c hemoglobin A1c, CKMB creatine 
kinase MB fraction, IQR interquartile range
Characteristics Statistic max n = 140
Gender (male) 86 (61.43%)
Age 71.24 ± 12.09
Degree of aortic stenosis
 None to trivial 10 (7.14%)
 Mild 0 (0%)
 Moderate 15 (10.71%)
 Severe 115 (82.14%)
Degree of aortic insufficiency
 None to trivial 61 (43.57%)
 Mild 38 (27.14%)
 Moderate 25 (17.86%)
 Severe 16 (11.43%)
LV EF (%) 57.36 ± 10.97
AX time (min) 81.73 ± 27.89
BMI (kg/m2) 30.76 ± 7.13
CAD (%) 67 (47.86%)
HgA1c (%) 6.08 ± 0.90
Day 1 CKMB (mcg/L) 32.00 ± 24.57
Pre ITLN1 (FPKM) 59.96 IQR 5.43–303.57 n = 132
Post ITLN1 (FPKM) 2.46 IQR 0.84–11.00 n = 132
Pre ITLN1 (ng/ml) 32.23 ± 15.22 n = 106
Post ITLN1 (ng/ml) 37.46 ± 16.84 n = 106
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described previously [21], but briefly, ribosomal RNA 
was removed by performing 1–2 washings of RNA 
annealed to poly-T oligos beads (Invitrogen). RNAs 
were reverse transcribed using random hexamers (Inv-
itrogen). Double-stranded DNA (dsDNA) synthesis was 
performed using Pol I and RNA-ase H. Short fragments 
were purified with QiaQuick PCR extraction kit (Qia-
gen) and resolved with EB buffer for end reparation and 
poly(A) addition then ligated with sequencing adap-
tors for cluster generation and sequencing on the Illu-
mina HiSeq 2000 (Illumina, San Diego, CA). As samples 
were analyzed at different times, different read lengths 
were employed, initially using single-end reads and then 
transitioning to paired-end reads ranging from 36 to 
100 base pairs.
Read alignment, transcript quantification, and differential 
gene expression analysis
Raw reads produced by the Illumina sequencer imag-
ing files were filtered to remove reads containing adap-
tor sequences, containing >5% unknown nucleotides, or 
having >50% of reads with base quality scores <5. Using 
Tophat v2.0.5 and Bowtie2 [22–24], reads were aligned to 
the Homo Sapiens reference genome (UCSC hg19). For 
paired-end reads, mate inner distance was set at 165 bp 
and mate standard deviation at 37 bp. For other param-
eters, we used the default settings in Tophat v2.0.5 and 
Bowtie2. Final read alignments having more than two 
mismatches or more than two gaps or more than two edit 
distances were discarded. The anchor length was 8 with-
out any mismatches being tolerated. The minimum and 
maximum intron lengths were 70 and 500,000 respec-
tively. The maximum insertion and deletion lengths were 
3. Fragments per kilobase per million mapped reads 
(FPKM) levels were determined using Cufflinks [25]. Dif-
ferential expression analysis was performed using Limma 
(v3.30.11) [26]. A linear model was constructed to test 
the effect of ischemia on gene expression, denoted y, 
while blocking on the patient from which each sample 
was collected, which adjusts for within and between-
sample variability:
where β denotes regression coefficients. Read counts 
were normalized while incorporating sample-level 
weights using voom [27], and genes were filtered for 
inclusion in differential expression analysis in accord-
ance with practices established by the authors of edgeR 
[28]. For each gene, positive or negative log2fold change, 
which was interpreted as an increase or decrease, respec-
tively, in gene expression due to ischemia, was deter-
mined. p-values were adjusted for multiple comparison 
testing using the Benjamini Hochberg method.
y ∼ β1(patient)+ β2 (ischemia)
Epicardial, visceral, and subcutaneous fat samples
Human visceral (omental) and abdominal subcutane-
ous adipose tissue samples were collected from patients 
undergoing weight loss reduction surgery at the Univer-
sity of Massachusetts Medical School between 2005 and 
2009 [29]. The microarray data from visceral (VAT) and 
subcutaneous adipose tissue (SAT) samples have been 
deposited in the GEO database under accession code 
GSE20950. Samples of epicardial adipose tissue (EAT) 
adjacent to the right coronary artery, and SAT from the 
sternum, were collected from patients without CAD who 
were having elective surgery for valvular heart disease. 
RNA was isolated using QIAGEN mini-lipid RNA extrac-
tion kits and analyzed on an Agilent 2100 Bioanalyzer. 
Complementary RNA (cRNA) synthesis and hybridiza-
tion to Affymetrix 1.0 ST microarrays was performed by 
the UMASS Medical School Genomics Core Facility. For 
both studies, informed consent was given by the patients 
and the study was approved by the University of Mas-
sachusetts Medical School Institutional Review Board. 
Subcutaneous (inguinal) and visceral (gonadal) adipose 
tissue was harvested from 13  week old male C57BL/6 
mice fed normal chow. RNA from paired samples (n = 6) 
was prepared with QIAGEN mini-lipid RNA extraction 
kits and analyzed on an Agilent 2100 Bioanalyzer. Com-
plementary RNA (cRNA) synthesis and hybridization 
to Affymetrix Mouse Gene 1.0 ST microarrays was per-
formed by the UMASS Medical School Genomics Core 
Facility. This data is publically available in the GEO data-
base under accession code GSE28440.
ITLN1 ELISA
Plasma samples were obtained from venous blood 
obtained before and after CPB in the same population 
of cardiac surgical patients from which the left ventricu-
lar biopsies were taken. Concentrations of ITLN1 were 
measured using ELISA (Millipore #EZH0MNTN1-29K) 
according to the manufacturer’s instructions.
ITLN1 Immunohistochemistry
Sections of EAT were fixed overnight in 10% formalin, 
sectioned, and stained for ITLN1 using a sheep anti-
human antibody (R&D Biosystems #AF4254) at 10 μg/ml. 
The secondary antibody was a donkey Anti-Sheep IgG 
NorthernLights NL557-conjugated antibody. Sectioning 
and immunofixation were done by the UMASS Morphol-
ogy core.
Mesothelial cell culture and qRT‑PCR
Primary human mesothelial cells were purchased from 
Zen-Bio. Cells were cultured according to the manufac-
turer’s instructions (Human Adult Mesothelial Cell Man-
ual ZBM0025.01). Briefly, cells were thawed and plated in 
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MSO-1 media at a density of 5000  cells/cm2. After they 
were 85–90% confluent, they were split at a 1:6 ratio and 
seeded onto collagen coated plates. On day 4, cells were 
serum starved for 24  h with Media 199 (Gibco) contain-
ing 5% penicillin/streptomycin, normocin, and 0.5% FBS. 
After 24 h, the media was changed and vehicle or 5 ng/ml 
TGFβ1(Sigma T7039) was added. Cells were harvested for 
RNA extraction after 48 h of TGFβ1 treatment. RNA was 
isolated using TRIzol as previously described. cDNA was 
synthesized with the iScript cDNA systhesis kit (BioRad) 
with 1  μg RNA template. qRT-PCR was performed using 
the iTaq Universal Sybergreen supermix (BioRad) and a 
CFX96 Connect Real Time Detection System. Relative 
expression was normalized to ribosomal phosphoprotein 
P0 (RPLP0) using the method of Livak et  al. [30]. Primer 
sequences were obtained from primer bank and were as 
follows: E-cadherin (CDH-1) (5′cgagagctacacgttcacgg 3′, 
3′gggtgtcgagggaaaaatagg 5′); VMAC (5′gccctagacgaactgggtc 
3′, 3′ggctgcaactgcctaatgag5′); fibronectin (5′cggtggct-
gtcagtcaaag3′, 3′aaacctcggcttcctccataa5′); SNAI1 (5′ tcg-
gaagcctaactacagcga 3′, 3′agatgagcattggcagcgag 5′); SNAI2 
(5′cgaactggacacacatacagtg 3′, 3′ctgaggatctctggttgtggt 5′).
Statistical analysis
Baseline continuous variable patient characteristics 
are presented as means and standard deviations except 
ITLN1 mRNA levels which are described with median 
and interquartile range. Categorical variables are 
described with total number and percentages. Differ-
ences between pre-ischemia and post-ischemia ITLN1 
protein levels and ITLN1 RNA levels were determined 
using a paired t test. Univariate linear regression analysis 
was performed on pre-ischemia ITLN1 RNA and ITLN1 
plasma levels against each other and clinical parameters 
including age, body mass index (BMI), hemoglobin A1c 
(HgA1c), sex, CAD, and post-operative day 1 creatine 
kinase MB fraction (CKMB). Similarly, univariate linear 
regression analysis was also conducted on post-ischemia 
ITLN1 RNA and ITLN1 plasma levels against the same 
clinical parameters in addition to aortic cross clamp time. 
These studies were conducted in R studio [31] using the 
general linear model function and results are reported as 
p-values and beta coefficients. p-value <0.05 was consid-
ered significant.
Results
Plasma ITLN1 protein levels increase while left ventricular 
ITLN1 RNA expression decreases following myocardial 
ischemia in humans
We used our prior CPB model in patients undergoing aor-
tic valve replacement to obtain pre-ischemia (blood and 
left ventricular tissue harvested at the start of CPB) and 
post-ischemia samples (tissue harvested after a mean of 
81.73 ± 27.89 min of ischemic cross clamp time) [21]. This 
model has previously been validated to mimic ischemia 
in human hearts [32, 33]. In a small cohort of patients, 
ITLN1 was the most significantly down-regulated gene 
in this model [21]. In the current larger study from 132 
paired samples, median levels of pre-ischemia and post-
ischemia left ventricular ITLN1 RNA expression were 
59.96 FPKM (interquartile range 5.43–303.57) and 2.46 
FPKM (interquartile range 0.84–11.00) respectively. In 
this population, post-ischemia RNA levels were signifi-
cantly lower than pre-ischemia levels (mean difference 
280.48, 95% CI 449.43–111.54, p = 0.001) (Fig. 1a). From 
the same group of patients, 106 paired samples had mean 
Fig. 1 ITLN1 expression is decreased in the left ventricle and circulating plasma levels of ITLN1 are increased following acute ischemia in the human 
heart. Stripcharts display the change in ITLN1 expression in left ventricular tissue samples (a) and in circulating ITLN1 protein levels following acute 
ischemia in the heart (b). FPKM: fragments per kilobase per million mapped reads
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pre-ischemia and post-ischemia ITLN1 plasma levels of 
32.23 ± 15.22 and 37.46 ± 16.84 ng/ml respectively. In this 
population post-ischemia protein levels were significantly 
higher than pre-ischemia levels (mean difference 5.24, 95% 
CI 3.52–6.95, p  <  0.001) (Fig.  1b). In patients with CAD 
compared to those without, pre-ischemia left ventricular 
expression levels of ITLN1 were slightly higher (median 
89.64 FPKM interquartile range 4.60–331.00 vs median 
43.53 interquartile range 5.62–281.85, p  =  0.839) while 
pre-ischemia plasma levels of ITLN1 were slightly lower 
(mean 30.94 ± 14.44 ng/ml vs mean 33.56 ± 16.03 ng/ml, 
p = 0.378) but these associations were not significant.
We next investigated the correlation between pre-
ischemia and post-ischemia ITLN1 expression in the left 
ventricle and clinical parameters using univariate linear 
regression models. There were no significant correlations 
identified. We repeated these correlations with plasma 
protein levels. Age was positively correlated with plasma 
protein levels before and after ischemia (Table 2). There 
were no significant associations of plasma protein levels 
or left ventricular expression of ITLN1 with patients on 
or off statin medications (data not shown).
Epicardial and visceral adipose tissue have a similar gene 
expression profile, characterized by enrichment of genes 
encoding proteins involved in innate immunity
Given the proximity of our cardiac biopsy samples to epi-
cardial adipose tissue (EAT), which has also been shown 
to express ITLN1 [8, 19], we further wanted to character-
ize the expression of ITLN1 in this compartment. Clinical 
studies have demonstrated that the amount of EAT cor-
relates with visceral adipose tissue (VAT), and is increased 
in aging and obesity [34, 35]. Therefore we hypothesized 
that the transcriptome of EAT may be similar to that of 
VAT, including high expression of ITLN1. In order to 
compare the gene expression profile of VAT with EAT, we 
utilized our previously published work [29]. We first com-
pared gene expression in paired SAT and VAT samples 
from eight non-diabetic patients who underwent weight 
reduction surgery. Next, we compared gene expression in 
paired EAT and SAT samples from nine patients without 
CAD having surgery for heart disease. We then evaluated 
the two sets of differentially regulated genes in order to 
indirectly compare the gene expression of EAT and VAT. 
In the paired VAT vs. SAT comparison, there was differ-
ential expression of 845 genes (Fold change >2.0, p < 0.05). 
In the paired SAT vs. EAT comparison, 188 genes were 
differentially expressed (FC > 2.0, p < 0.05). Of these 188 
genes, 46% were commonly differentially regulated in 
VAT (Fig. 2). These included ITLN1 and other canonical 
VAT specific genes such as TCF21, SRFP2, and ALOX15 
(Table 3). Remarkably, geneset enrichment analysis of the 
differentially expressed genes in both the SAT vs. VAT 
and SAT vs. EAT comparison yielded almost identical 
results (Table 4). The top three enriched pathways in VAT 
and EAT included complement, classical complement, 
and lectin induced complement. Therefore, even in the 
absence of CAD or diabetes, both VAT and EAT seem to 
play an important role in innate immunity.
ITLN1 expression is localized to the mesothelium 
and downregulated following epithelial to mesenchymal 
transition
Next, we aimed to more carefully characterize the 
expression of ITLN1 in EAT. We first confirmed that 
Table 2 Univariate correlations between  ITLN1 RNA 
expression and  circulating levels of  ITLN1 protein 
with clinical parameters
BMI body mass index, HgA1c hemoglobin A1c, CAD coronary artery disease, 
CKMB creatine kinase MB fraction, AX time aortic cross clamp time
* Denotes significance
Characteristic Beta p‑value
Pre-ischemia ITLN1 RNA
 Age 1.586 0.81
 BMI −0.40 0.971
 HgA1c −1.05 0.99
 Sex (male) −18.42 0.91
 CAD 32.15 0.839
 Day 1 CKMB 1.80 0.582
 ITLN1 pre-ischemia protein −1.06 0.879
Post-ischemia ITLN1 RNA
 Age 1.08 0.683
 BMI −0.43 0.923
 HgA1c −29.44 0.404
 Sex (male) −4.55 0.944
 CAD −2.97 0.962
 Day 1 CKMB −0.39 0.756
 AX time −0.50 0.660
Pre-ischemia ITLN1 protein
 Age 0.30 0.022*
 BMI −0.20 0.340
 HgA1c 2.18 0.225
 Sex (male) 3.37 0.260
 CAD −2.36 0.424
 Day 1 CKMB −0.01 0.900
 ITLN1 pre-ischemia RNA −0.0002 0.879
Post-ischemia ITLN1 protein
 Age 0.37 0.011*
 BMI −0.26 0.250
 HgA1c 1.64 0.410
 Sex (male) −1.00 0.765
 CAD −0.24 0.942
 Day 1 CKMB −0.04 0.524
 AX time −0.01 0.862
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expression of ITLN1 is highly enriched in human VAT, 
and nearly absent in SAT (Fig. 3a). Similar to other stud-
ies [7, 8], we also were able to show that ITLN1 expres-
sion in human VAT is isolated to the stromal vascular 
fraction (SVF) (Fig.  3b). Mice, on the other hand, have 
equivalent low levels of ITLN1 expression in both VAT 
and SAT (Fig. 3c).
Since the SVF can contain multiple different cell types 
including epithelial cells, macrophages, fibroblasts, and 
precursory adipocytes [7], we sought to further char-
acterize the location of ITLN1 in EAT. Immunohisto-
chemistry demonstrated that ITLN1 is predominantly 
localized to the mesothelium, which constitutes the 
visceral pericardium, and not the adjacent adipocytes 
(Fig. 4a–d).
We then wanted to determine if ITLN1 expression 
requires an epithelial cell fate. Primary human meso-
thelial cells were treated with TGFβ1 (5 ng/ml) for 48 h 
in order to induce epithelial to mesenchymal transition. 
qRT-PCR demonstrated that ITLN1 RNA expression was 
dramatically reduced within 48 h (Fig. 5a). We also con-
firmed that expression of ITLN1 was absent in a human 
adipocyte cell line before and after adipogenic differenti-
ation (SGBS D0 and D14); whereas the adipocyte specific 
gene Perilipin 1 (PLIN1) was increased dramatically in 
this cell line, but not in the mesothelial cells (Fig.  5b). 
Furthermore, using qRT-PCR, we confirmed that the 
decreased ITLN1 mRNA expression was paralleled by an 
early transition to a mesenchymal lineage, characterized 
by increased expression of the mesenchymal markers 
VMAC, SNAI1, and SNAI2 (Fig. 5c). Interestingly, many 
genes that have been shown to play a role in the epithe-
lial to mesenchymal transition were among the complete 
list of RNA-seq differentially expressed genes from our 
pre- and post-ischemic human myocardial samples. In 
particular, there was upregulation of the mesenchymal 
markers MMP9, TCF4, BMP1, and SNAI2, and down-
regulation of the epithelial markers KRT19 and CDH-1 
(Additional file 1: Table S1).
Discussion
This is the first study to demonstrate changes in ITLN1 
expression in a large cohort of human left ventricular 
tissue samples following acute ischemia. We show that 
pre-ischemia levels of ITLN1 expression in the human 
myocardium are much higher than the nominal levels 
depicted in the GTEX consortium [36]. This is likely a 
result of the tissue samples being immediately placed 
Fig. 2 Venn diagram of differentially regulated genes between subcutaneous adipose tissue (SAT) vs. visceral adipose tissue (VAT) and epicardial 
adipose tissue (EAT) vs. SAT. In the SAT vs. VAT comparison, 845 genes were differentially regulated (FC > 2.0, p < 0.05). In the EAT vs. SAT comparison 
188 genes were differentially regulated. 46% of these were commonly differentially regulated in VAT in comparison to SAT (middle overlapping seg-
ment). The numbers in each circle indicate the number of genes whose expression was altered; numbers in bold italic are upregulated, those in red 
font are contraregulated, and those in underlined plain font are downregulated in the respective comparisons. The specific genes are listed in Table 3
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in preservative unlike other samples exposed to longer 
periods of inadvertent ischemic time prior to harvesting. 
The ischemic insult of CPB led to a dramatic decrease 
in ITLN1 reads to very low detectable levels in most 
patients. Given results from prior studies which have 
shown a cardioprotective function of ITLN1 [5, 17], 
this decrease in endogenous ITLN1 RNA may make the 
heart vulnerable to further injury. There was also a nega-
tive correlation between aortic cross clamp time and the 
level of post-ischemia ITLN1 mRNA, although with the 
lack of significance we cannot conclude with certainty 
that longer ischemic time leads to lower levels of ITLN1 
mRNA in the myocardium.
Prior studies have shown that plasma levels of ITLN1 
are low in patients with CAD [12, 19]. The plasma levels 
of ITLN1 prior to acute ischemia in our study were also 
lower in patients with known CAD, although this dif-
ference was not statistically significant. The response to 
acute ischemia has been less studied. One group showed 
that patients with acute coronary syndrome (ACS) have 
lower levels of plasma ITLN1 than healthy controls [13]. 
Our study using a large number of paired tissue samples, 
on the other hand, demonstrated an increase in plasma 
ITLN1 levels. This difference was significant regardless 
of underlying CAD. Those patients in the prior study 
with ACS likely had chronic levels of ischemia prior to 
presentation, and that may have been the driving force 
behind lower levels of ITLN1. As a result, chronic lev-
els of low grade ischemia, as present in patients with 
CAD, may lead to low levels of plasma ITLN1, but acute 
ischemia may cause an abrupt increase. Future stud-
ies are needed to determine the source of this increased 
pool of circulating ITLN1. It could originate from the 
myocardium, which combined with lower levels of RNA 
expression would expose this organ to even more injury, 
or it could come from a visceral fat compartment in the 
body in order to rescue low myocardial expression. We 
did not identify a correlation between circulating levels 
of pre-ischemia ITLN1 protein and the myocardial injury 
marker CKMB on post-operative day 1. Nevertheless, 
the low variance in CKMB levels in our study does not 
refute other studies that have shown a potential protec-
tive effect of ITLN1 towards myocardial ischemia.
In agreement with previous work, we show that ITLN1 
is also expressed in EAT and localized to the SVF [7, 8, 
37]. We further expand this knowledge by showing that 
ITLN1 is confined to the mesothelial cells of the visceral 
pericardium or epicardium in human tissue through 
immunohistochemistry. Recent studies have shown that 
the mesothelial layer plays critical roles in development 
and disease processes in fat tissue in part due to its abil-
ity to secrete regulatory substances in a paracrine fash-
ion [38]. This localization is additionally supported by 
evidence that ITLN1 expression is dependent on an 
epithelial cell fate as expression levels decrease follow-
ing an epithelial to mesenchymal transformation. Inter-
estingly, ischemic injury has been shown to stimulate an 
epithelial to mesenchymal transition in the epicardium, a 
process that can donate cells of multiple lineages to the 
myocardium [39, 40]. Many genes known to play a role 
in the epithelial to mesenchymal transition were dysregu-
lated in our myocardial samples following ischemia. As a 
result, although it is possible that the changes in ITLN1 
expression may come from myocytes in our biopsies, it 
is also possible that these changes occur in a population 
of cells that can undergo an epithelial to mesenchymal 
Table 3 Genes whose expression are commonly regulated in visceral adipose tissue (VAT) and epicardial adipose tissue 
(EAT) in comparison to subcutaneous adipose tissue (SAT)
Commonly up regulated in VAT and EAT (n = 56) Contra regulated in VAT 
and EAT (n = 3)
Commonly down regulated in VAT and EAT 
(n = 28)
ITLN1,TGM1, PROX1, IL18, C3, FRAS1, PDPN, PLAT, UPK3B, PDE1A, 
CGNL1, OSR1, GATA6, KCNT2, C21orf62, FBLN1, DSC3, TFF3, RELN, 
SULF1, CFI, FLRT3, PLLP, SLC39A8, GLT8D4, BCHE, MEIS2, PTPRD, 
ALDH1A2, HSD17B6, GPM6A, ART4, TIMP1, DKFZP586H2123, SYT4, 
BNC1, MSLN, PTGDS, LRP2, TGM2, ITGB8, PTN, ALOX15, C4A//C4B, 
CLDN1, RARRES1, INMT, MMRN1, UPK1B, SLPI, C7, TCF21, CKMT1A, 
CCL21, HP, PKHD1L1,
SFRP2, CD36, CHI3L2 NNAT, C12orf39, CXCL14, CRHBP, XG, ALDOC, ABCD2, 
EGFL6, ADRA2A, MFAP5, CPM, APOB, SIM1, SIX1, 
NOVA1, TBX15, SNX10, ENPP1, MME, OSR2, CDKN2B, 
DGAT2, FOSB, CCND1, TNN, TBX5, ZFP36, KLB
Table 4 Gene set enrichment analysis of  pathways 
enriched in  epicardial adipose tissue (EAT) and  visceral 
adipose tissue (VAT) vs. subcutaneous adipose tissue (SAT)
Enrichment (%) p‑value
Epicardial adipose tissue
 Classical complement pathway 28 <0.001
 Lectin induced complement pathway 25 <0.001
 Complement pathway 21 <0.001
 Cell/molecules of local acute inflamma-
tory response
17 <0.001
Visceral adipose tissue
 Classical complement pathway 28 <0.001
 Complement pathway 26 <0.001
 Lectin induced complement pathway 25 <0.001
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Fig. 4 Immunohistochemistry of ITLN1 in epicardial adipose tissue (EAT) shows enrichment within the mesothelial cell layer. Subcutaneous adipose 
tissue (SAT) stained for ITLN1 (a). EAT stained for ITLN1 (b) with magnification of the mesothelial cell layer of the visceral pericardium (c). Secondary 
antibody alone was used as a control (d). ITLN1 red, DAPI blue
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Fig. 3 ITLN1 is specifically expressed in the stromal vascular fraction of visceral fat in humans. a Microarrays were queried for expression of ITLN1 in 
visceral adipose tissue (VAT) vs. subcutaneous adipose tissue (SAT) in paired samples (n = 8) (*** p < 0.001). b ITLN1 expression from microarrays of 
the adipocyte and stromal vascular fraction (SVF) of VAT in paired samples (n = 6) (** p < 0.01). c Expression of ITLN1 from microarrays of murine SAT 
and VAT
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transition following injury such as the vascular endothe-
lium, the endocardium, the epicardium, or cells in 
transition from the endocardium/epicardium to the myo-
cardium. Additional studies are required to further define 
this cell population.
Conclusions
This is the first study to demonstrate an acute decline 
in left ventricular ITLN1 expression following ischemia 
in a large cohort of surgical patients. This is paralleled 
by an increase in plasma protein levels. We also pro-
vide evidence to suggest that the expression of ITLN1, 
similar to other secreted factors in the heart, may be 
dependent on an epithelial cell fate. Future studies will 
be needed to validate the precise sources and targets of 
ITLN1 in the heart in order to further define its protec-
tive capabilities.
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Fig. 5 ITLN1 expression in primary mesothelial cells is dramatically reduced following an epithelial to mesenchymal transition. a qRT-PCR for ITLN1 
in mesothelial cells ± TGFβ1 and in a human adipocyte cell line (SGBS) before (D0) and after differentiation (D14) (n = 6 per group). b qRT-PCR for 
the adipocyte specific gene PLIN1 in mesothelial cells ± TGFβ1 and in a human adipocyte cell line (SGBS) before (D0) and after differentiation (D14)
(n = 6 per group). c Expression of the epithelial cell marker CDH-1 and the mesenchymal cell markers VMAC, SNAI1, and SNAI2 before and after treat-
ment of mesothelial cells with TGFβ1 (n = 6 per group)
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